The initial report consisted of 21 children and young adults with R/R CD22+ B-ALL, including multiply relapsed patients who had all undergone HSCT and 15 of whom had also received prior CD19 CAR-T therapy. Here, CD19 is linked to acute lymphoblastic leukemia.